Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Polymyxin B in Renal Insufficiency
NCT05359627Phase 1Completed
- Sponsor
- TTY Biopharm Company Limited
- Start
- Jul 2022
- Primary completion
- Mar 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of polymyxin B in Gram-negative bacterial infection (3 arms), sponsored by TTY Biopharm Company Limited. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve to Last Timepoint at 48 hours and 2 more. Started Jul 2022; status: completed.
02
Drugs
polymyxin B
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT05359627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359627.